3 New Strong Buy Ratings from Top-Rated Analysts: 06/16/2026
Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Jazz Pharmaceuticals (JAZZ) — Biotech leader targets 33% upside on robust pipeline.
- Generac Holdings (GNRC) — Power generation giant rides AI data center boom.
- Moog (MOG.A) — Defense/aerospace play hits fresh 52-week highs ahead.
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
Windfall Profit Potential For These 5 Summer Stocks From peak travel demand to the World Cup to home improvement season, summer drives the business behind each of these 5 companies. This free report covers the catalysts, fundamentals and analyst price targets. Click here to access your free copy.1. Generac Holdings (NYSE: GNRC)
A global supply agreement with a leading hyperscale data center operator has positioned this power generation specialist right at the center of the AI infrastructure boom. Manufacturing power generation equipment and other engine-powered products for residential, commercial, oil, gas, and industrial markets, Generac is emerging as one of the most overlooked AI plays on the market.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $270.08 — get current quote
Max 1-year forecast: $335.00
Why we're watching:
- Analyst support: Among the 14 analysts we track issuing recommendations, GNRC earns 10 Strong Buys, 2 Buys, and 2 Holds. See all coverage here.
- For example, on the bullish side, Canaccord Genuity analyst George Gianarikas (a top 8% rated analyst) recently maintained his Strong Buy rating with a price target that suggests over 20% upside potential in the coming year, praising Generac's innovative product pipeline and robust demand forecasting.
- Industry ranking context: GNRC is currently the #1 highest-rated stock in the Specialty Industrial Machinery industry, which has an Industry Rating of B.
- Zen Rating highlights: GNRC earns an overall Zen Rating of A, which amounts to a Strong Buy recommendation. This means that after a rigorous 115-factor review, the stock came out in the top 5% of all stocks in our 4600+ stock database.
- Component Grades: Each Zen Rating is composed of 7 Component Grades. GNRC earns an exceptional A grade for Growth, and an above-average B grade for Financials — a combo that indicates the company has a solid balance sheet while maintaining robust growth prospects. (See all 7 Zen Component Grades here)
2. Moog (NYSE: MOG.A)
No, this is not the synth music company. But the stock is making sweet music with its price action. Fresh 52-week highs signal that this precision motion specialist is firing on all cylinders. Designing and manufacturing precision motion and fluid controls and controls systems for aerospace, defense, and industrial markets, Moog is gaining recognition for its strategic positioning in the booming defense and space sectors.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $406.09 — get current quote
Max 1-year forecast: $450.00
Why we're watching:
- Analyst support: Moog does not have a ton of analyst coverage, but what it has is bullish. TD Cowen's Gautam Khanna (a top 8% rated analyst) recently maintained his Strong Buy rating with a $450 price target, explaining that he favors Moog stock because of the company's self-help margin headroom aiding mix, its cost footprint, and its prospects for a high-single-digit percent sales CAGR.
- Despite strong fundamentals, Khanna acknowledged that "investor awareness remains low because of limited sell-side coverage," suggesting significant upside potential as more analysts begin coverage.
- Industry ranking context: MOG.A is currently the 4th highest-rated stock out of 85 in the Defense industry — a nice rank, but note that the industry itself has a rating of D.
- Zen Rating highlights: Moog enjoys a Zen Rating of A, which amounts to a Strong Buy recommendation. The stock’s Component Grade scorecard reveals several strengths worth noting: Its Momentum (B), Sentiment (B), Safety (B), and Financials (B) grades reflecting the company's stable operations and growth prospects. (See all 7 Zen Component Grades here)
3. Jazz Pharmaceuticals (NASDAQ: JAZZ)
The undisputed leader of the Biotech industry keeps delivering despite recent trial setbacks. As a global biopharmaceutical firm dedicated to discovering, advancing, and bringing to market innovative medicines for conditions where treatment options are lacking, Jazz is winning over Wall Street with its robust pipeline and strong growth trajectory across key therapeutic areas.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $230.56 — get current quote
Max 1-year forecast: $307.00
Why we're watching:
- Analyst support: Roughly 90% of analysts covering the stock recommend JAZZ as a Buy or Strong Buy, with price targets pointing to over 30% implied upside in the coming year. See all recommendations
- For example, UBS researcher Ashwani Verma (a top 11% rated analyst) upgraded the stock to Strong Buy with a $307 price target (33% upside potential), emphasizing that brand loyalty and product efficacy are critical for market capture.
- Industry ranking context: JAZZ is currently the #1 highest-rated stock in the Biotech industry.
- Zen Rating highlights: JAZZ earns an overall Zen Rating of A or Strong Buy, putting it in a class of stocks that have historically delivered nearly 30% annual returns over the past 20 years.
- Component Grades: JAZZ earns exceptional marks across the board with As for Growth and Value, and strong Bs for Financials and Momentum. (See all 7 Zen Component Grades here)
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.